Integra LifeSciencesIART
Market Cap: $1.44B
About: Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Employees: 3,946
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
36% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 73
0.16% more ownership
Funds ownership: 89.88% [Q1] → 90.04% (+0.16%) [Q2]
15% less funds holding
Funds holding: 277 [Q1] → 236 (-41) [Q2]
17% less capital invested
Capital invested by funds: $2.49B [Q1] → $2.07B (-$426M) [Q2]
53% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 77
81% less call options, than puts
Call options by funds: $312K | Put options by funds: $1.68M
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
BTIG Ryan Zimmerman 56% 1-year accuracy 19 / 34 met price target | 8%upside $20 | Sell Maintained | 28 Aug 2024 |
Citigroup Joanne Wuensch 66% 1-year accuracy 25 / 38 met price target | 8%upside $20 | Sell Maintained | 22 Aug 2024 |
JMP Securities David Turkaly 59% 1-year accuracy 16 / 27 met price target | 89%upside $35 | Market Outperform Maintained | 30 Jul 2024 |
Truist Securities Richard Newitter 67% 1-year accuracy 29 / 43 met price target | 41%upside $26 | Hold Maintained | 30 Jul 2024 |
Citigroup Joanne Wuensch 66% 1-year accuracy 25 / 38 met price target | 24%upside $23 | Sell Downgraded | 30 Jul 2024 |
Financial journalist opinion
Based on 3 articles about IART published over the past 30 days